1 Major Factor Behind the Healthcare Sector's Recent Surge

Blockbuster drug momentum is driving recent healthcare outperformance, with the S&P 500 Health Care index up roughly 5.1% over the past month versus the S&P 500’s 2.3%; key catalysts include Eli Lilly’s tirzepatide becoming the world’s best‑selling drug in Q3 (Lilly +9.1% month‑to‑date), Merck’s Keytruda sales rising 10% YoY and topping $8 billion for the quarter (Merck +18.2%), AbbVie’s Skyrizi sales jumping 46.8% to $4.7 billion and Rinvoq up 35.3% to ~$2.2 billion with management targeting $20 billion and $11 billion respectively, and Johnson & Johnson’s announced acquisition of Halda Therapeutics (JNJ +8.6%); collectively these product-level gains are creating meaningful revenue and valuation tailwinds for large-cap drugmakers and are prompting increased investor focus on pipeline, launch sustainability and deal activity.

Analysis

The S&P 500 Health Care Sector has outperformed the broader market recently, rising about 5.1% over the past month versus the S&P 500's ~2.3%, driven largely by blockbuster drug performance. Eli Lilly's tirzepatide became the world’s best-selling drug in Q3 and Lilly's stock is up 9.1% month-to-date, signaling strong commercial momentum for its GLP-1 franchise.

AbbVie reported Skyrizi sales of $4.7 billion in Q3, up 46.8%, and Rinvoq sales near $2.2 billion, up 35.3%, with management targeting $20 billion for Skyrizi and $11 billion for Rinvoq in annual revenue, underpinning ABBV's recent gains. Merck's Keytruda sales rose 10% year-over-year and topped $8 billion for the quarter, while Merck is up 18.2% month-to-date; Johnson & Johnson announced the Nov. 17 acquisition of Halda Therapeutics and JNJ is up 8.6% for the month.

The news is creating clear revenue and valuation tailwinds for large-cap drugmakers and has produced moderately positive market sentiment (aggregate sentiment score 0.6) with per-ticker strength highest for MRK (0.8). Investors should prioritize monitoring sustained sales trajectories, upcoming guidance and deal execution as the primary determinants of whether recent gains are durable or pricing already reflects peak expectations.

Key Decisions for Investors

• Consider initiating or adding selective exposure to large-cap drugmakers showing durable top-line growth (Merck, AbbVie, Eli Lilly) after confirming upcoming quarterly trends and management guidance
• Monitor Keytruda, Skyrizi, Rinvoq and tirzepatide sales prints and guidance as leading indicators of revenue sustainability and rerate risk
• Treat M&A activity such as J&J's Halda acquisition as a tactical catalyst and reassess position sizes around deal announcements and related integration guidance
• If exposure is sizable, implement portfolio risk controls (position sizing or hedges) until there is clearer evidence these launches can meet multi-year revenue targets